Our goal is that all patients, whoever they are and wherever they live, can have access to effective treatment to treat and overcome the lesions caused by HPV. For this reason, since the launch of the Papilocare® family in 2016, we have strengthened and consolidated our international presence in different parts of the planet. And we will continue to do so to go even further.

Currently, the treatment can be found on four continents and in nearly 60 countries, including its recent entry into the Chinese market.